The main effects and target mechanisms of Aceminib

Asciminib (Asciminib) is a new type of tyrosine kinase inhibitor (TKI), mainly used to treat chronic myelogenous leukemia (CML), especially in patients with previous treatment failure or T315I mutation. It has shown good efficacy. It is the first so-called "STAMP inhibitor" (Specifically Targeting the ABL Myristoyl Pocket) drugs have a more selective and innovative mechanism of action compared with traditional TKIs, providing a new option for targeted treatment of CML.

The main target of Asiminib is the "myristoyl acid binding site" in the BCR-ABL1 fusion protein (myristoyl pocket), this region is different from the ATP binding site inhibited by the first and second generation TKI. Aceminib binds to the myelic acid pocket and changes the conformation of BCR-ABL1 protein, thereby inhibiting its kinase activity. This mechanism not only avoids the problem of common resistance mutations, but also maintains good inhibitory activity in the context of traditional TKI resistance such as T315I mutation.

In terms of clinical application, Asiminib is mainly used to treat patients in the chronic phase of CML who have failed two or more TKIs in the past. It is especially suitable for refractory patients carrying the T315I mutation. In clinical studies, aximinib has demonstrated a higher molecular response rate and a lower incidence of adverse reactions. Compared with traditional drugs such as imatinib and nilotinib, its safety and tolerability are better, especially in long-term maintenance treatment.

Overall, aximini, as a third-generation TKI with novel targets, has brought breakthrough progress in the precise treatment of chronic myelogenous leukemia. It not only provides new treatment hope for patients who are ineffective in conventional TKI treatment, but also indicates that the development of targeted drugs will move towards more refined site binding. In the future, with the accumulation of more clinical trial data, the application scope of aceminib is expected to be further expanded, and it may become the standard for certain CML patients.First-line treatment options for subtypes.

Reference materials:https://www.novartis.com/our-products/pipeline/asciminib

xa0